Ocugen Completes Enrollment for OCU400 Gene Therapy Phase 3 Trial
Summary
Ocugen has announced the completion of patient enrollment for its Phase 3 liMeliGhT trial of OCU400, a gene therapy targeting retinitis pigmentosa, with 140 patients now enrolled. This milestone is a significant de-risking event for the company's lead clinical asset, indicating the trial is progressing as planned and moving closer to potential regulatory submission. For a clinical-stage biotech, advancing a Phase 3 program is a critical value driver. Investors will now look towards the next major catalyst, which is the expected release of topline data in early 2027. The headline also noted an analyst projection of a 6-cent loss per share in the upcoming earnings report, which is an expected outcome for a development-stage company and less impactful than the clinical trial progress.
At the time of this announcement, OCGN was trading at $1.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $636.1M. The 52-week trading range was $0.52 to $1.96. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.